UW Study Links GLP-1 Use and Gambling Behavior, Seeks Participants 2026

University of Washington researchers are studying potential links between GLP-1 medication use and gambling behavior, compensating study participants.

Anton Voronov

Anton Voronov

B2B Analyst

2 min read
16
0
UW Study Links GLP-1 Use and Gambling Behavior, Seeks Participants 2026

University of Washington Launches Gambling-GLP-1 Medication Research Initiative

The Addictions, Drug & Alcohol Institute (ADAI) at the University of Washington has opened recruitment for the GAME Study, an academic research project examining potential associations between GLP-1 medication use—including medications like Ozempic and Wegovy—and gambling participation and behavior patterns.

Participants who use GLP-1 medications and engage in gambling activities are eligible to join the study and receive compensation for their participation. The research represents one of the first formal academic investigations into this emerging behavioral intersection.

Why This Intersection Matters

GLP-1 medications have gained significant cultural and medical prominence over the past three years, initially developed for diabetes management but increasingly prescribed off-label for weight loss. As adoption has grown, public health researchers have begun investigating potential behavioral and cognitive side effects or correlations.

Simultaneously, gambling participation rates have risen across both regulated and unregulated channels as sports betting legalization has expanded and digital gaming platforms have proliferated. The GAME Study represents an effort to understand whether GLP-1 use may influence gambling behavior patterns—either protective or risk-elevating—and whether concurrent use creates specific addiction or problem gambling profiles.

Research Implications

If the study identifies statistically significant associations between GLP-1 use and gambling behavior, results could inform clinical screening protocols in addiction medicine and potentially influence responsible gaming framework development in regulated iGaming markets. Operators already track player demographics and behavioral metrics; pharmacological correlations could add a new dimension to risk assessment and player protection systems.

The research may also inform treatment pathways for individuals struggling with concurrent pharmaceutical use and problem gambling, potentially revealing whether addiction treatment protocols should be tailored based on medication profiles.

Broader Pattern

This study exemplifies growing academic interest in examining how pharmaceutical and behavioral patterns interact within addiction frameworks. As iGaming continues to expand and normalize across markets, research linking medication use to gambling participation may become increasingly common, particularly around medications affecting reward pathways or impulse control.

Source: casino.org

academic researchGLP-1 medicationsgambling behavioraddiction researchUniversity of Washingtonresponsible gamingclinical studyparticipant recruitment
Anton Voronov

Anton Voronov

B2B Analyst

Member of the iGaming Pulse editorial team. Covering industry news, analysis, and B2B developments across the global iGaming sector.

0 Comments

Leave a Comment

Related Articles

Newsletter

Stay ahead of the iGaming industry

Weekly briefings covering regulation, operator moves, B2B deals, and market analysis — delivered free to your inbox every Thursday.

No spam. Unsubscribe at any time. 5,000+ industry professionals already subscribed.